ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Olof Zachrisson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.